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For the last 50 years, levodopa has been the cornerstone of Parkinson’s disease management. However, a majority
of patients develop motor complications a few years after therapy onset. Deep brain stimulation has been
approved by the FDA as an adjunctive treatment in Parkinson disease, especially aimed at controlling these
complications. However, the exact mechanism of action of deep brain stimulation, the best nucleus to target as
well as the best timing for surgery are still debatable. We here provide an in-depth and critical review of the current
literature on this topic.
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Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the clinical tetrad of motor dysfunction,
including tremor, rigidity, akinesia (or bradykinesia) and
postural instability (TRAP). It has a prevalence of 1 to
2% above the age of 60 years [1] and typically develops
between the ages of 55 and 65 years. The tremor typically
starts asymmetrically and is present at rest, usually in-
volving hands, legs, jaw, lips, but sparing the head.
Pathologically, PD is classified as a synucleinopathy, as-
sociated predominantly with the loss of dopaminergic
neurons in the substantia nigra, but other brainstem
neurons have been found to degenerate in PD, possibly
contributing to not only motor but also non-motor
impairment [2]. Indeed, PD is now considered to be a
complex syndrome, and is no longer regarded as a pure
motor system disorder [3]. For example, neurobehavioral
abnormalities are frequent in advanced PD and include
depression, dementia, bradyphrenia, apathy, fearfulness,
anxiety, emotional lability, social withdrawal, visual–spatial
impairment, sleep disturbance and psychosis. Autonomic
involvement leads to constipation, bladder and sphincter
dysfunction and orthostatic hypotension. Dermatological
problems such as seborrhea, sensory problems such
as pain and tingling, and special sense disorders such
as hyposmia and vestibular dysfunction are also well
described [3].* Correspondence: eclai@tmhs.org
2Department of Neurology, Houston Methodist Neurological Institute, 6560
Fannin, Suite 802, Houston 77030, TX, USA
Full list of author information is available at the end of the article
© 2013 Mehanna and Lai; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumFive years after initiation of therapy, a majority of pa-
tients develop medication related motor complications,
namely levodopa induced dyskinesias (LID) and motor
fluctuations. LID are choreic, stereotypic, and dystonic
movements affecting any part of the body [2] and occur-
ring either at peak dose or when the medication is kicking
in or wearing off (dyskinesia-improvement-dyskinesia ef-
fect). Motor fluctuations occur when the duration of each
medication dose is too short and the symptoms of PD
recur sooner that initially. This weaning off the medication
effect can occur suddenly and unexpectedly, leaving the
patient with markedly decreased mobility and/or severe
tremor [4,5]. Deep brain stimulation (DBS) has been devel-
oped primarily to address these treatment related motor
complications and therapeutic failures.
The estimated annual health care cost of PD ranges
from $2,000 to more than $20,000 per patient [6], with an
estimated global economic burden of $4.63 billion [7], the
greatest part of which being represented by nursing homes
and personal care-giving [8-10] which are much higher in
the later stage PD [11].Brief overview of the motor circuitry of the basal
ganglia
To better understand the hypothesized mechanism of
action of DBS in PD, we will first briefly review the
motor circuitry of the basal ganglia. Different motor
and non-motor cortical areas project primarily to the
striatum which has two major projections: the direct
pathway to the globus pallidus pars interna (GPi) and
the indirect projection to the GPi via the globus pallidusntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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GPi serves as the major output nucleus, which connects
back to the cortex via the thalamus. Modulated by the
substantia nigra pars compacta, the indirect pathway
exerts surround inhibition and thus facilitates an excita-
tory drive to muscles responsible for a given movement
and suppresses unwanted motor activity not relevant to
the primary movement. Thus, PD is thought to result
from over-activation of the indirect pathway leading to
an increased output from the GPi and a decrease in
spontaneous movement [12]. This model of the basal
ganglia and its connections is, of course, an oversimplifica-
tion of a complex network that, when disrupted, can result
in a range of motor abnormalities [13]. For example, a
hyperdirect pathway, projecting directly from the cortex
to the STN, and from there to the GPi has recently been
added to this model [14].
Pathophysiology of PD
The loss of dopaminergic neurons in the substantia
nigra, the main functional characteristic of PD, affects
the circuit described above and leads to the cardinal
motor symptoms of PD. While the exact mechanism of
this process is unknown, animal research as well as
human recordings have provided functional and bio-
chemical evidence that bradykinesia in PD results from
excessive activity in the STN and the GPi [3,15-17]. This
leads to an exaggerated beta (10-30 Hz) synchronization
within and between structures in the basal ganglia
circuitry [3] that could also contribute to rigidity and
akinesia [18,19].
The pathophysiology of rest tremor in PD is less clear
and probably more complicated. The existence of a unique
pacemaker driving the tremor in the thalamus or the
GPi has been suggested and then rejected [3]. This
symptom most likely results from a dysfunction of both
the striato-pallidal-thalamocortical and the cerebello-
dentato-thalamocortical circuits [20], with hyperactivity
and hypersynchronization between central oscillators [21].
However, contrary to bradykinesia, tremor does not seem
to be dependent on beta oscillatory synchronization [22,23].
Possible mechanism of action of DBS
DBS acts through delivering an electrical current in a
specific target area of the brain. This current can be
modulated through modification of voltage, frequency
and duration of each electrical pulse delivered. The de-
livered energy creates an electrical field of variable size
and shape according to the parameters used for stimu-
lation. Although initially believed to stimulate the tar-
get, thus the name of the whole process, it seems that
DBS actually excites the neuronal fibers, but inhibits
the neural cells [24,25]. In fact, GPi DBS decreases the
GPi mean firing rate back to a normal range in animalmodels as well as PD patients [26], and high frequency
DBS has a similar effect as dopamine replacement
therapies, and promotes faster (about 70 Hz) non-
hypersynchronous activity in the basal ganglia, corre-
lated with clinical improvement [27-30]. This might be
achieved through stimulation of bypassing inhibitory
pathways, synaptic inhibition, depolarizing blockade,
synaptic depression, and simulation-induced disruption
of pathological network activity [26,31]. Overall, this
leads to modifications of the firing rate and pattern of
neurons [32] in the basal ganglia, as well as local release
of neurotransmitters such as glutamate and adenosine
[33-35]. In addition, it seems that DBS also increases
blood flow and stimulates neurogenesis [36].
Over the last few years, functional imaging, specifically
functional magnetic resonance imaging (fMRI), positron
emission tomography (PET) and single-photon emission
computed tomography (SPECT), has been used in an
attempt to clarify the mechanism of action of DBS. In
fMRI, blood-oxygen-level-dependent (BOLD) signals are
acquired, and oxygenated blood marks areas of neural
stimulation or inhibition [37-39]. On the other hand,
PET and SPECT allow for imaging of multiple activity
markers, such as blood flow, glucose and oxygen metab-
olism [40,41]. While fMRI is less powerful than nuclear
medicine techniques, it provides a much better spatial
and temporal resolution.
Because of the suspected inhibitory DBS effects in
electrophysiological studies, reduced STN blood flow or
glucose metabolism would have been expected on func-
tional imaging. However, the opposite has been found to
be true in an overwhelming majority of imaging studies to
date [42-49]. In addition, BOLD activation in the area sur-
rounding the electrode has been reported [48,49], despite
the electrode imaging artifact preventing direct observa-
tion of the STN around the electrode. This discrepancy
between apparent STN inhibition in single-cell studies
and activation in imaging studies might be explained by a
few hypotheses [50]. First, electrophysiological recordings
identify short neuronal modulation (in the order of
milliseconds) while neuroimaging methods may reflect
the summed activity changes over seconds to minutes.
Second, non-neuronal contributions to the change in
blood flow and/or glucose metabolism cannot be ex-
cluded, and could confound the results of neuroimag-
ing. Finally, it is possible that PET and fMRI actually
detect the increased activity in the axons, rather than
in the cell bodies. Complicating matters further, some
imaging studies after STN DBS have showed increased
activity in the GPi [47,48,51] while others reported
decreased activity in that nucleus [42,52].
In summary, it is still unclear how exactly DBS affects
the firing rate and pattern of neurons and how these
changes actually modify the symptoms of Parkinson’s
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treatment in search of physiological explanation.
Clinical aspect
The effect of DBS on the cardinal symptoms of PD have
been established in three randomized controlled clinical
trials (Table 1) [53-55].
The first trial was conducted in Germany and Austria
on 156 patients with PD and persistent motor symptoms
despite optimal medical therapy [53]. These patients
were randomly assigned to DBS of the STN (STN DBS)
or optimal medical management. DBS assigned patients
had a statistically better quality of life, as measured by
the Parkinson’s Disease Questionnaire-39 (PDQ-39), as
well as motor symptoms control, as measured by the
motor part of the Unified Parkinson’s Disease Rating
Scale (UPDRS, Part III). Another trial conducted in the
United States as a double-blinded randomized study and
involving 255 patients showed that DBS in either the
STN or GPi increased the amount of dyskinesia free ON
time at 6 months by 4.6 hours compared to the optimally
managed medical group [54]. The statistically significant
improvement in quality of life after DBS compared to
optimal medical management was reproduced in a third
trial on 366 patients followed for 1 year in the United
Kingdom [55].
These and other studies have also shown that DBS
typically improves “off” time by 4 to 6 hours per day
[54,56,57], and reduces off symptoms by 60% and medica-
tion induced dyskinesias in STN DBS by 60-80% [58]. In
addition to the improvement of motor symptoms, DBS
can also improve pain, emotion, akathisia and even auto-
nomic function as reported in 3 of 11 patients [58-63].
In some studies, working memory and psychomotor
speed improved in the ON versus OFF stimulation state
of bilateral STN DBS [64]. Open label studies and pro-
spective series also suggest that bilateral as well as uni-
lateral STN DBS improves sleep quality and increases
total sleep time, likely by allowing a better control of
PD symptoms at night and by a direct effect on sleep
architecture (Table 2) [65-67].
DBS is a reasonable option to consider when medica-
tion adjustments do not control disabling symptoms
anymore [6,66,68]. However, not all such PD patients
are candidates for DBS, and a thorough multidisciplinaryTable 1 Randomized controlled trial comparing DBS to optim
Author, year Number of patients Follow up
Deuschl et al., 2006 [53] 156 6 months
Weaver et al., 2009 [54] 255 6 months
Williams et al., 2010 [55] 366 12 months
Legend: BL: bilateral; STN: subthalamic nucleus; GPi: Globus pallidum pars interna; DBscreening process is required to determine those who
are good candidates [69,70]. In the current context of re-
ducing unnecessary expenses, this screening process can
be staged to help reduce costs and improve its efficiency.
Patients should first undergo a thorough clinical evalu-
ation from the neurologist to ascertain the diagnosis and
exclude other causes of parkinsonism, such as vascular
parkinsonism or Parkinson Plus Syndromes that are re-
fractory to DBS. The neurologist should optimize med-
ical management before offering DBS. Patients should
then discuss at length with the neurologist and neuro-
surgeon to assess their understanding of the risk/benefits
ratio of the surgery. If the patients then clearly under-
stand this commitment and wish to proceed, the ON
levodopa/OFF levodopa motor testing can be performed.
In the ON/OFF testing, the patient is asked to withhold
all PD medications for 12 hours before undergoing
examination with the UPDRS. The patient is then given
his regular dose of levodopa and the UPDRS is adminis-
tered again after the patient reports feeling the full effect
of this dose. ON and OFF UPDRS scores are compared
and an improvement of at least 30% after medication
intake is typically recommended to proceed to the
next step. Indeed, only the symptoms that improve
with levodopa are expected to improve with DBS, with
the notable exception of medication refractory tremor
that can still improve after surgery. DBS should thus
be offered to patients with levodopa-responsive symp-
toms [71]. At that point, if the patient is still considered
a good candidate for surgery, brain MRI, neuropsycho-
logical testing and psychiatry evaluation would be
pursued.
Animal models of PD have suggested that STN DBS
might prevent further neuronal loss and thus have a
neuroprotective effect [72-77]. The mechanisms of
such effect are unknown, but could include a reduc-
tion in excitotoxic induced damage [76]. However,
these results have not yet been reproduced in the few
human studies evaluating DBS for a neuroprotective
effect [78,79].
Similar to the medical management of PD, DBS is
thus a symptomatic treatment and has not been shown
to slow the progression of the disease. The duration of
the therapeutic benefit has not been clearly established,
but modifying the parameters of the stimulation allowsal medical management
Target Results (primary outcome)
BL STN -Quality of life better with DBS
-Motor symptoms better with DBS.
BL STN or GPi Dyskinesia- free ON time 4.6 hours longer with DBS
BL STN or GPi -Quality of life better with DBS
S: deep brain stimulation.
Table 2 Summary of benefits and side effects of DBS
Reported benefits Reported side effects
Improved QOL Wound/hardware infection
Decreased OFF time Intra cranial hemorrhage
Reduced OFF symptoms Post-operative seizures
Reduced LID Muscle twitches or tonic contractions
Improved sleep Paresthesia











Legend: DBS: deep brain stimulation; QOL: quality of life; LID: levodopa
induced dyskinesias.
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patient’s symptoms and evolution, and sustained clinical
improvement had been reported up to 10 years after im-
plant [80-84]. However, the greatest sources of disability
in late-stage PD, including drug-resistant axial motor
features and non-motor symptoms, especially psychiatric
disorders and cognitive decline, are not significantly modi-
fied by DBS [85].
Occasionally, patients might have a suboptimal response
to DBS. In a series of 41 such patients, 31 of whom ini-
tially diagnosed with PD, Okun et al. [86] reported poor
patient screening and selection as the main causes for
DBS failure. Other causes included improper electrode
location as well as suboptimal DBS programming and
medication management. 51% of these patients markedly
improved with appropriate management adjustments [86].
Occasionally, patients might require surgical lead reposi-
tioning or even the addition of another lead in another
brain structure [87].
While DBS related expenses such as the hardware,
surgery, post-surgical programming visits and personal
care-giving are relevant [88], STN DBS seems economic-
ally more beneficial than optimal medical management
through a decrease in drug requirement and cost as well
as a reduction in nursing care cost [58,89-91]. No such
data exist for GPi DBS.
Side effects
Like all surgeries, DBS implant is not deprived of potential
complications (Table 2). The rate of post-operative woundor hardware infection varies from 1.2% to 15.2% in differ-
ent series [92-94], and most often such incidences require
removal of the hardware in addition to an antibiotic
course [6,94]. Intracranial hemorrhage has been reported
in 5% of cases, but was symptomatic only in 2.1% of
implanted patients and caused a permanent deficit or
death in 1.1% [95]. Another larger study reported 1% of
intracranial hemorrhage and stroke respectively, in 299
patients after DBS placement [57]. Older age and a
history of hypertension have been associated with an
increased risk of hemorrhage [95]. Post-operative sei-
zures were reported in 2.4% of patients in one review
[96], but these do not increase the risk of epilepsy.
Prophylactic anticonvulsive therapy before and around
surgery is currently unjustified.
Because the energy delivered to the target can spread
to nearby structures and alter their function as well,
DBS can induce cognitive and speech impairment, visual
complaints, mood disorders including suicidal ideation
[97,98], dysphagia, paresthesia and muscle twitches or
tonic contractions. These are most frequently due to a
lead positioned too close to the medial STN, optic tract,
oculomotor nerve, internal capsule or lemniscal tract.
Ideally, these side effects could be reduced or avoided by
optimal placement of the lead, with a combined use of
anatomic localization and intraoperative microelectrode
recording. In addition, using bipolar stimulation settings
will create a smaller field with less spreading to adjacent
structures, and consequently fewer side effects. The
most frequent cognitive side effect to DBS seems to be a
decrease in verbal fluency, especially when the STN is
targeted [99], although some authors argue this to be a
consequence of the implant rather than the stimulation
[6]. In a trial comparing 123 patients randomized to bi-
lateral STN DBS or optimal medical management with
neuropsychological and psychiatric evaluations at base-
line and at 6 months, there was a selective decrease in
frontal cognitive function, especially verbal fluency and
naming in the DBS group. However, overall cognition
was preserved and anxiety was more improved in that
group [100]. Other reported neuropsychiatric adverse ef-
fects include anxiety, apathy [101,102], decreased frontal
cognitive function [100], decreased executive function
[103], impulse control disorders, obsessive-compulsive
disorder and aggression [104-108]. Poor pre-operative
affective state may predict continued depression post DBS
[109], highlighting the need for appropriate pre-surgical
patient screening. Finally, DBS can also lead to weight
gain [110].
These side effects are more frequent in bilateral pro-
cedures [111], and a unilateral implantation can also
have bilateral benefits [111-113]. The decision to im-
plant unilaterally or bilaterally needs to be tailored to
the patient’s needs.
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Once a patient is determined to be a good candidate
for DBS, a target for the procedure has to be selected.
Ablative surgery or DBS of the ventral intermediate
(Vim) nucleus of the thalamus is being used for essential
and other secondary causes of tremor. However, because
it does not address the other cardinal motor symptoms of
PD, Vim DBS is rarely used for that disorder [114]. The
two main targets considered for DBS in PD are the STN
and the GPi (Table 3).
Anderson et al. [115] conducted the first randomized
controlled trial comparing STN DBS and GPi DBS. This
trial included only 20 patients followed for 12 months
and showed both targets to be equally effective for im-
proving PD motor symptoms and dyskinesia. It also
showed a greater decrease in dopaminergic medication
use in the STN group (p = 0.08) as well as cognitive and
behavioral complications exclusively in that group.
The COMPARE trial [116] included 45 patients with
unilateral GPI or STN DBS who were followed for
7 months. The 2 targets were similar in motor control
improvement and side effects profiles including mood
and cognition, except for worsening of verbal fluency in
the STN DBS group. However, GPi DBS patients had a
bigger improvement in their quality of life compared to
STN patients (38 vs. 14%, respectively; P = 0.03) with
decrease in verbal fluency potentially contributing to
less improvement in the STN patients [117]. In a followTable 3 Randomized controlled trials comparing STN and GPi
Author, year Number of
patients
Follow up Side Similar result
Anderson et al.,
2005 [115]
20 12 months Bilateral -Motor sympt
Okun et al.,
2009 [116]













128 12 months Bilateral -Quality of life
-Cognitive, ps
behavioral sid
Legend: STN: subthalamic nucleus; GPi: Globus pallidum pars interna; DBS: deep brainup to the COMPARE trial including 52 patients, unilat-
eral STN DBS implant carried a 5.2 times increased risk
to require a contralateral DBS implant at 3 years, when
compared to unilateral GPi DBS implant [112].
In a large multicenter randomized control trial, Follett
et al. [57] followed 299 patients for 2 years. GPi and
STN DBS were similar in motor control improvement
and side effects profiles, except for more severe decline
in visuomotor processing as well as requiring lower
doses of dopaminergic medications in STN DBS patients
(p = 0.03 and 0.02 respectively). In addition, the level of
depression improved in the GPi DBS group while it
worsened in STN DBS patients (p = 0.02). At the 3-year
follow-up of the same group, including 159 patients,
Weaver et al. [118] showed that the 2 targets were similar
in motor control improvement and side-effect profiles, ex-
cept for worse cognitive performance in the STN group at
3 years (p = 0.01). This study also confirmed the greater
reduction in dopaminergic drugs in the STN group.
The most recent double blinded randomized con-
trolled trial comparing STN and GPi DBS [119] included
128 patients and reproduced the lack of significant dif-
ference in quality of life improvement between the 2 tar-
gets at 1 year. However, there was greater improvement
in the OFF phase motor score and disability in STN DBS
patients (p = 0.03). This study also confirmed a greater
decrease in dopaminergic medication doses in the STN
group (p = 0.01). However, there was no difference inDBS
s Differences in results
oms -Greater decrease in dopaminergic drug dosage
with STN.
-Cognitive and behavioral complications
exclusively with STN.
oms. -Worse verbal fluency with STN.
including mood and -Greater improvement in QOL with GPi [117].
-Higher risk to require controlateral DBS implant
in STN group [112].
oms. -Greater decrease in dopaminergic drug dosage
with STN.
rofile. -Worse decline in visuomotor processing with STN
-Depression improved with GPi but worsened
with STN.
oms. -Greater decrease in dopaminergic drug with STN.
rofile. -Worse cognitive performance with STN




-Greater improvement in the OFF phase motor
score with STN
- Greater improvement in disability with STN
stimulation; QOL: quality of life.
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the 2 groups.
It is unclear why STN DBS might have a higher rate
of cognitive decline and/or depression in some studies.
These finding first need to be reproduced, but both
current spreading to limbic regions as well as the de-
creased dose of dopaminergic drugs might be contribu-
tory [120]. Taking all these data into consideration, the
current tendency is to prefer targeting the STN because
of a greater improvement in the OFF phase motor
symptoms as well as a higher chance to decrease the
medication dosage and a lower battery consumption
linked to the use of lower voltage in the STN compared
to the GPi DBS. Lower battery consumption correlates
with longer battery life and thus less frequent surgery to
replace it [119]. On the other hand, GPi DBS has a dir-
ect anti-dyskinestic effect when stimulation is delivered
to the ventral part of the nucleus, while decrease in LID
after STN DBS can be achieved through the decrease in
medication dose. For that reason, GPi can be the preferred
target if LID is the main complaint. As most studies
showed that STN DBS resulted in more cognitive and
behavioral deficits [57,115,116,118], GPi DBS might be
preferred for patients with mild cognitive impairment
and psychiatric symptoms.
Because of its role in locomotion, the pedunculopontine
nucleus (PPN) has been suggested as a DBS target to ad-
dress gait difficulty and freezing of gait, which are typically
resistant to STN or GPi DBS. A few small observational or
open labeled studies have been conducted, evaluating PPN
DBS as an add-on to STN DBS [82,121-126]. Precise ana-
tomical lead locations as well as results were controversial,
and PPN DBS cannot be recommended at this point.
Timing of the surgery
Currently, patients are not considered for DBS unless they
do not tolerate levodopa, become resistant to medications
or have complications from medical therapy, while still
being medically and psychologically fit for surgery.
Some authors suggest that exhausting all pharmacological
options before considering DBS can delay the surgery to a
time when the patient is no longer fit because of disease
progression [58,127,128].
A small randomized trial of bilateral STN DBS in 10
patients with early PD (mean duration of 7 years) com-
pared to 10 matched medically treated controls [129]
showed a significant benefit from DBS on quality of life,
motor control and decrease in levodopa doses. More re-
cently, Schuepbach et al. [130] conducted a randomized
controlled trial comparing bilateral STN DBS to optimal
medical management in 251 PD patients aged less than
60 years, with PD for more than 4 years but with motor
fluctuations and dyskinesia for 3 years or less. This
study demonstrated improvement in quality of life,motor control, as well as mood at 24 months in the
DBS group compared to the medical group. Mild side
effects were more frequent in the DBS group, but the
incidence of moderate to severe side effect was compar-
able between the 2 groups. With a mean age of onset of
52 years as compared with 59 to 62 years in other trials
[55-57,80,119] and a mean duration of PD of 7.5 years,
as compared with 10.8 to 13.8 years [53,55-57,119], this
study demonstrated the added benefit of early DBS in
PD symptoms control, when medical treatment is still
effective. However, these results have yet to be confirmed.
Another ongoing trial comparing DBS early in the course
of PD to optimal medical management, EARLYSTIM
[58,131], involves 247 patients implanted a mean of
7.5 years after diagnosis and within 3 years of development
of treatment induced motor complications. Preliminary
results report a mean age of 52 years, levodopa therapy
duration of 4.9 years and fluctuations and/or dyskinesias
present for 1.5 or 1.7 years respectively. At 2 years follow
up, quality of life and motor control were superior in the
DBS group. Side effects were more frequent in the medical
group, and surgical complications resolved entirely.
In addition, an analytic model of STN DBS, defined by
off time and applied at an early versus delayed stage,
concluded that early DBS increases quality-adjusted life
years and reduces treatment costs [132]. However, further
studies in this area are warranted before recommending
early DBS placement in PD patients. In addition, it would
be wise to wait 5 years after the onset of symptoms before
performing the surgery, in order to rule out any Parkinson
Plus Syndrome.
Conclusion
For the last 50 years, levodopa has been the cornerstone
of PD management. However, a majority of patients
develop motor fluctuations and/or LID about 5 years
after the initiation of therapy. DBS of the STN or the
GPi grant to patients with PD improved quality of life
and decreased motor complications, and has been ap-
proved as such by the Food and Drug Administration in
the US in 2002. We reviewed the experience and avail-
able literature on DBS for Parkinson’s disease over the
last decade and arrive at the following suggestions. (1)
The success of DBS surgery depends on the accurate
placement of the leads and meticulous programming of
the stimulation. Therefore, it is best accomplished by an
experienced team of neurosurgeon, neurologist, and
support staff dedicated to the treatment. (2) Reports of
surgical complication rates and long-term side-effects
of DBS are very variable, so benefits and potential ad-
verse results should not be under- or over-emphasized.
(3) While essentially equal in improving the motor
symptoms of PD, STN and GPi might have their own
benefits and risks, and the choice of the target should
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(4) Knowledge to further improve DBS treatment for
Parkinson’s disease, such as a more scientific and reli-
able protocol on programming, strategies to minimize
cognitive and psychiatric complications, and the better
long-term maintenance of the implanted device, are still
lacking. (5) Data on the impact of DBS on non-motor
symptoms affecting the quality of life of PD patients,
such as pain, speech or gastro-intestinal complaints, are
still scarce. Further research in these areas will help
make this useful treatment even more beneficial.
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